Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer
Status:
Terminated
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and efficacy of maintenance therapy
with daily low dose lenalidomide in patients with stage IIIB/IV non-small cell lung cancer
(NSCLC) after first line chemotherapy. Investigators expect this treatment approach will
delay disease progression by boosting the patient's anti-tumor immune response. Investigators
hypothesize that 10 mg/day of lenalidomide can be administered safely as maintenance therapy
and improve progression free survival time.